JAK2 and ovarian carcinoma: Nie et al. demonstrated that demethylase ALKBH5 was significantly upregulated in cisplatin-resistant ovarian cancer and activated JAK2/STAT3 pathway by mediating JAK2 m6A demethylation to promote the resistance to cisplatin [57].